胞内分枝杆菌氯法齐明耐药新型突变研究
本研究在体外分离36株氯法齐明耐药的胞内分枝杆菌突变体,通过全基因组测序发现61%的突变体携带marR基因突变,基因互补实验证实marR是氯法齐明耐药的关键决定因子,且其机制与结核分枝杆菌不同,不导致贝达喹啉交叉耐药。
要点
- marR基因突变存在于61%的氯法齐明耐药胞内分枝杆菌突变体中。
- 导入野生型marR可将氯法齐明MIC从1 mg/L降至0.25 mg/L。
- 胞内分枝杆菌marR突变不导致贝达喹啉交叉耐药。
核心结论
- marR是胞内分枝杆菌氯法齐明耐药的关键决定因子,其调控机制与结核分枝杆菌不同。
研究设计与样本
- 体外分离36株氯法齐明耐药的胞内分枝杆菌突变体,进行全基因组测序和基因互补实验验证。
主要发现
- 61%的氯法齐明耐药突变体携带marR基因(WP_009952290.1)突变。
- 其他突变基因包括ssuD(C67A)、lppI(C207缺失)、GMC氧化还原酶(G157缺失)、MASE1结构域蛋白(C62G)和PPE家族蛋白(222C缺失)。
- 在携带marR突变的耐药株L72中导入野生型marR,氯法齐明MIC从1 mg/L降至0.25 mg/L。
- 胞内分枝杆菌MarR与结核分枝杆菌Rv0678(MmpR)无同源性,其突变不导致贝达喹啉交叉耐药。
关键数值与推荐
- 氯法齐明耐药突变体marR突变频率为61%。
- 野生型marR互补后氯法齐明MIC从1 mg/L降至0.25 mg/L。
临床怎么用
- marR可作为胞内分枝杆菌氯法齐明耐药的分子检测靶点,有助于快速识别耐药和指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clofazimine is a promising repurposed drug for treating Mycobacterium avium-intracellulare complex pulmonary disease, but its resistance mechanisms in Mycobacterium intracellulare remain poorly understood. OBJECTIVE: This study aims to elucidate the resistance mechanisms of M. intracellulare to clofazimine. METHODS: We isolated 36 clofazimine-resistant M. intracellulare mutants in vitro and performed whole-genome sequencing to identify resistance-associated mutations. Gene complementation was used to validate the role of the identified mutations. RESULTS: We identified various mutations in the marR gene (WP_009952290.1) in 61% of clofazimine-resistant mutants by whole-genome sequencing. Mutations were identified in additional genes encoding ssuD (flavin-dependent oxidoreductase, C67A), lppI (membrane lipoprotein, C207 deletion), GMC oxidoreductase (glucose-methanol-choline oxidoreductase, G157 deletion), MASE1 domain-containing protein (C62G) and PPE family protein (222C deletion). Gene complementation experiments demonstrated that introducing the wild-type marR in clofazimine-resistant strain (L72) with marR mutations reduced clofazimine MIC from 1 mg/L to susceptible baseline (0.25 mg/L), confirming its critical role in clofazimine resistance. Notably, the M. intracellulare MarR lacks homology to Mycobacterium tuberculosis MarR family protein Rv0678 (MmpR) involved in clofazimine and bedaquiline resistance but is flanked by non-efflux pump genes (dhmA and doxX), and unlike M. tuberculosis, its mutation does not cause bedaquiline cross-resistance, indicating a different MarR and distinct regulatory mechanism for clofazimine resistance in M. intracellulare. CONCLUSIONS: This work highlights marR as a key determinant of clofazimine resistance in M. intracellulare and underscores the need for further mechanistic studies with implications for rapid molecular detection and effective treatment.
引用
- Jiang X, Cao D, Qiu Y, et al. Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare. J Antimicrob Chemother. 2025. PMID: 40905483. doi:10.1093/jac/dkaf321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。